Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

BACKGROUND: The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States. Our single center’s experience with Impella 5.5® can expand the overall understanding for achieving successful patient outcomes as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Rock, Joanna R., Kos, Cynthia A., Lemaire, Anthony, Ikegami, Hirohisa, Russo, Mark J., Moin, Danyaal, Dulnuan, Kenneth, Iyer, Deepa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128113/
https://www.ncbi.nlm.nih.gov/pubmed/35606780
http://dx.doi.org/10.1186/s13019-022-01871-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128113/
https://www.ncbi.nlm.nih.gov/pubmed/35606780
http://dx.doi.org/10.1186/s13019-022-01871-1

Ejemplares similares